← Back to patent-cliff list
MHV-370
Tier C — Watch / tradeMHV-370
Novartis Pharmaceuticals Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：TLR7, TLR8
Indications (approved)：Sjögren's syndrome, 混合性结缔组织病, Systemic lupus erythematosus
Regional status
US
-
EU
Discontinued
2021-11-30
China
Discontinued
2021-11-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MHV-370?
Approved indications include: Sjögren's syndrome, 混合性结缔组织病, Systemic lupus erythematosus.
When does the MHV-370 patent expire?
No public expiry year is available for MHV-370 yet; this page updates once verified.
How do I get a quote for MHV-370 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21